Skip to main content

Table 3 Demographics and clinical background of participants (N = 1080)

From: Incidence of adverse reaction of drugs used in COVID-19 management: a retrospective, observational study

Variable Patients with ADR (n = 217) Patients without ADR (n = 863) P value
Age (mean ± SD in years) 47.96 ± 16.50 40.07 ± 16.51 < 0.001
Sex
     Male 137 (63.1%) 593 (68.7%) 0.116
     Female 80 (36.9%) 270 (31.3%)  
History of drug allergy
     Yes 5 (2.3%) 26 (3.0%) 0.576
     No 212 (97.7%) 837 (97.0%)  
Presence of comorbidity
     Yes 117 (53.9%) 294 (34.1%) < 0.001
     No 100 (46.1%) 569 (65.9%)  
COVID-19 category
     Patient under investigation 9 (4.1%) 80 (9.3%)  
     Stage 1 1 (0.5%) 35 (4.1%)  
     Stage 2 27 (12.4%) 357 (41.4%)  
     Stage 3 85 (39.1%) 311 (36.0%)  
     Stage 4 79 (36.4%) 58 (6.7%)  
     Stage 5 16 (7.4%) 22 (2.5%)  
Number of COVID-19 drug(s)
     1 51 (23.5%) 704 (81.6%)  
     2 96 (44.2%) 115 (13.3%)  
     3 46 (21.2%) 30 (3.5%)  
     4 and 5 24 (11.1%) 14 (1.6%)  
  1. Data are n (%) or mean (± SD)
  2. Analysed with Mann–Whitney U test
  3. Analysed with Chi-square (X2) test